grant
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer
Organization UNIVERSITY OF TX MD ANDERSON CAN CTRLocation HOUSTON, UNITED STATESPosted 5 Apr 2024Deadline 31 Mar 2029
NIHUS FederalResearch GrantFY2026APAF-3APAF3Adoptive TransferAllogenicApaf-3 proteinApoptosis-Related Cysteine Protease Caspase 9Apoptosis-Related Cysteine Protease Gene Caspase 9Apoptotic Protease Activating Factor 3Apoptotic Protease Activating Factor 3 GeneApoptotic Protease MCH-6Apoptotic Protease MCH-6 GeneAutologousB cell malignancyB lymphoid malignancyB lymphomaB-Cell LymphomasBasal Transcription FactorBasal transcription factor genesBiopsyCAR NKCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCASP-9CASP9CASP9 ProteinCASP9 geneCD19CD19 geneCancer TreatmentCancersCaspase-9 GeneCell BodyCell Communication and SignalingCell SignalingCell Surface AntigensCell Surface GlycoproteinsCell TherapyCellsClinicClinicalClinical ResearchClinical StudyCord BloodCryofixationCryopreservationCyclic AMP Response ElementCytotoxic cellDataDoseEffector CellEndowmentEventExhibitsFDA approvedGene DeletionGene ModifiedGeneral Transcription Factor GeneGeneral Transcription FactorsGenerationsGvHDHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHomologous Wasting DiseaseICE-LAP6ICE-LAP6 GeneICE-LAP6 proteinICE-Like Apoptotic Protease 6ICE-Like Apoptotic Protease 6 GeneIL-15IL15IL15 ProteinImmune TargetingImmunological Surface MarkersImmunosuppressionImmunosuppression EffectImmunosuppressive EffectIn VitroInterleukin-15Interleukin-15 PrecursorIntracellular Communication and SignalingK lymphocyteLactic acidLymphocytic NeoplasmLymphocytic TumorLymphocytic and Plasma Cell NeoplasmLymphocytic and Plasma Cell TumourLymphocytic and Plasmacytic NeoplasmLymphoid CellLymphoid TumorLymphoid and Plasma Cell TumourLymphoid and Plasmacytic NeoplasmLymphoid and Plasmacytic TumourMCH6MGC9721Malignant Hematologic NeoplasmMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant TumorMalignant neoplasm of pancreasMch6 proteinMembrane GlycoproteinsMetabolicMultiple MyelomaNK CellsNK cell immune therapyNK cell immunotherapyNK cell therapyNK cell treatmentNK cell-based immune therapyNK cell-based immunotherapyNK cell-based therapyNK cell-based treatmentNK cellular immunotherapyNK cellular therapyNK immunotherapyNK therapyNK treatmentNatural Killer Cell ImmunotherapyNatural Killer CellsNormal TissueNormal tissue morphologyPDA modelPDAC ModelPancreas CancerPancreas Ductal AdenocarcinomaPancreatic CancerPancreatic Ductal AdenocarcinomaPatientsPhase 1/2 Clinical TrialPhase I/II Clinical TrialPlasma-Cell MyelomaPopulationProliferatingProteomicsProtocolProtocols documentationPublishingReportingResearchResistanceRetroviral VectorRetrovirus VectorRunt DiseaseSafetySecondary toSignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSpecificitySurface AntigensSurface GlycoproteinsSurvival RateT cells for CART-CellsT-LymphocyteTestingTimeToxic effectToxicitiesTranscription Factor Proto-OncogeneTranscription factor genesTranslationsTumor AntigensTumor CellTumor-Associated AntigenUmbilical Cord Bloodaerobic glycolysisanti-cancer therapybiobankbiological signal transductionbiorepositorycAMP Response Elementcancer antigenscancer microenvironmentcancer therapycancer-directed therapycaspase-9cell based interventioncell mediated interventioncell mediated therapiescell transductioncell-based therapeuticcell-based therapycellular therapeuticcellular therapycellular transductioncheck point inhibitioncheckpoint inhibitionchimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor engineered natural killer cellchimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellschimeric antigen receptor natural killer cellscold preservationcold storagecostcytokineeffective therapyeffective treatmentengineered NK cellengineered natural killer cellfabrication costfetal cord bloodfirst in manfirst-in-humanfitnessgene deletion mutationgene modificationgenetically engineered cellsgenetically modifiedgenetically modified cellsgraft versus host diseasegraft vs host diseasegraft vs. host diseasehuman studyimmune check pointimmune check point inhibitionimmune checkpointimmune checkpoint inhibitionimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmunecheckpointimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentimproved outcomein vitro Modelin vivoinnovateinnovationinnovativeintraperitoneallymphoid neoplasmmalignancymanufacturemanufacturing costmanufacturing processmetabolic fitnessmouse modelmurine modelmyelomamyelomatosisnatural killer cell based immune therapynatural killer cell based immunotherapynatural killer cell therapynatural killer cell treatmentnatural killer cell-based therapynatural killer cells expressing chimeric antigen receptorsnatural killer cells with chimeric antigen receptorsnatural killer cellular therapynatural killer therapyneoplasm/cancerneoplastic cellnew approachesnext generationnovelnovel approachesnovel strategiesnovel strategypancreatic cancer patientspancreatic ductal adenocarcinoma modelpancreatic malignancypatients with pancreatic cancerperipheral bloodpharmacologicpoint of carepre-clinicalpreclinicalresistantresponsesafety testingsuccesstherapeutic targetthymus derived lymphocytetranscription factortranscriptomicstransduced cellstranslationtrophoblasttumortumor immune microenvironmenttumor microenvironmenttumor-immune system interactionstumor-specific antigen
Description preview
SUMMARY/ ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a 5-year survival rate of only ~12%.
Therefore, there is a critical unmet need for new treatment options. Chimeric antigen receptor (CAR)-T cells
have led to a paradigm shift in the treatment of some hematologic cancers, but efficacy in solid tumors remains…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click